( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Objective The aim of this study was to estimate the efficacy of elagolix , an oral gonadotropin-releasing hormone ( GnRH ) antagonist , for the treatment of endometriosis-associated pelvic pain . Methods This was a phase II , r and omized , placebo-controlled parallel group study conducted at 37 US centers , consisting of an 8-week double-blind period followed by a 16-week open-label period . Patients were 137 women aged 18 to 49 , with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea , who were administered elagolix 150 mg daily or placebo . The primary outcomes of the study were the daily assessment of dysmenorrhea , nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale . Results During the double-blind period , there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea ( -1.13 ± 0.11 vs. −0.37 ± 0.11 , p<0.0001 ) , nonmenstrual pelvic pain ( -0.47 ± 0.07 vs. −0.19 ± 0.07 , p = 0.0066 ) , and dyspareunia scores ( -0.61 ± 0.10 vs. −0.23 ± 0.10 , p = 0.0070 ) in the elagolix group compared with placebo . Continued improvements were observed during the open-label treatment regardless of initial treatment allocation . Elagolix treatment was also associated with significant improvements in quality -of-life measures during the double-blind and open-label periods . The most common adverse events occurring with elagolix were nausea , headache and hot flush , each in 9.9 % of patients . Conclusion Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .